Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
American Journal of Physiology. Cell Physiology|August 13, 2010
SV2 regulates neurotransmitter release via multiple mechanismsAmy Nowack, Jia Yao, Kenneth L Custer, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|January 27, 2006
Synaptic vesicle protein 2 enhances release probability at quiescent synapsesKenneth L Custer, Naola S Austin, Jane M Sullivan, et al.
Molecular and Cellular Neurosciences|May 4, 2005
SV2A and SV2C contain a unique synaptotagmin-binding siteAmanda E Schivell, Sumiko Mochida, Patricia Kensel-Hammes, et al.
Journal of Neuroscience Methods|April 26, 2011
A high-throughput method for generating uniform microislands for autaptic neuronal culturesAllyson E Sgro, Amy L Nowak, Naola S Austin, et al.
The New England Journal of Medicine|October 28, 2020
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19Peter Chen, Ajay Nirula, Barry Heller, et al.
JAMA|January 21, 2021
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical TrialRobert L Gottlieb, Ajay Nirula, Peter Chen, et al.
The New England Journal of Medicine|July 14, 2021
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19Michael Dougan, Ajay Nirula, Masoud Azizad, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 31, 2021
A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral LoadMichael Dougan, Masoud Azizad, Bharat Mocherla, et al.
JAMA|June 3, 2021
Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical TrialMyron S Cohen, Ajay Nirula, Mark J Mulligan, et al.
Pageof 1